Lys343

Site Information
VLRDIVHkPGPIVLT SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12338464

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 5 , 6 , 7 , 8 , 9 ) , microscopy-colocalization with upstream kinase ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:	breast cancer ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 1 ) , HEp-2 (squamous) ( 2 ) , Jurkat (T lymphocyte) ( 2 , 5 , 6 ) , MDA-MB-231 (breast cell) ( 1 ) , U266 (plasma cell) ( 7 , 8 , 9 )

Downstream Regulation
Effects of modification on DVL2:	intracellular localization ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:	cell motility, induced ( 1 ) , signaling pathway regulation ( 1 )
Induce interaction with:	Cofilin-1 (human) ( 1 ) , VANGL1 (human) ( 1 )

References
1	Nielsen CP, et al. (2019) USP9X Deubiquitylates DVL2 to Regulate WNT Pathway Specification. Cell Rep 28, 1074-1089.e5 31340145 Curated Info
2	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
3	Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171 29079793 Curated Info
4	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info
7	Guo A (2009) CST Curation Set: 8646; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
8	Guo A (2009) CST Curation Set: 8643; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info
9	Guo A (2009) CST Curation Set: 8645; Year: 2009; Biosample/Treatment: cell line, U266/Velcade; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990 Curated Info